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Abstract 
Background: Despite advances in targeted therapy for lung cancer, survival for patients remains poor and lung 
cancer remains the leading cause of cancer-related deaths worldwide. The type I insulin-like growth factor receptor 
(IGF-IR) has emerged as a potential target for lung cancer treatment, however, clinical trials to date have provided 
disappointing results. Further research is needed to identify if certain patients would benefit from IGF-IR targeted 
therapies and the ideal approach to incorporate IGF-IR targeted agents with current therapies.
Methods: The dual IGF-IR/insulin receptor inhibitor, BMS-754807, was evaluated alone and in combination with 
platinum-based chemotherapeutics in two human non-small cell lung cancer (NSCLC) cell lines. Cell survival was 
determined using WST-1 assays and drug interaction was evaluated using Calcusyn software. Proliferation and apop-
tosis were determined using immunofluorescence for phospho-histone H3 and cleaved caspase 3, respectively.
Results: Treatment with BMS-754807 alone reduced cell survival and wound closure while enhancing apoptosis in 
both human lung cancer cell lines. These effects appear to be mediated through IGF-IR/IR signaling and, at least in 
part, through the PI3K/AKT pathway as administration of BMS-754807 to A549 or NCI-H358 cells significantly sup-
pressed IGF-IR/IR and AKT phosphorylation. In addition of BMS-754807 enhanced the cytotoxic effects of carboplatin 
or cisplatin in a synergistic manner when given simultaneously to A549 cells.
Conclusions: BMS-754807 may be an effective therapeutic agent for the treatment of NSCLC, particularly in lung 
cancer cells expressing high levels of IGF-IR.
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Background
Lung cancer remains the leading cause of cancer-related 
deaths worldwide [1], and non-small cell lung cancer 
(NSCLC) represents ~80  % of the cases of lung cancer 
[2]. Lung cancer is often not diagnosed until later stages 
[3, 4] when it is no longer responsive to the standard 
treatment which is based on platinum chemotherapeutics 
and radiation [5–7]. Despite the development of a num-
ber of new targeted therapies against epidermal growth 
factor receptor (EGFR), vascular endothelial growth 
factor (VEGF), and anaplastic lymphoma kinase (ALK), 
overall survival rates remain poor [7–10]. There is a need 
to develop new treatment strategies including new drugs 
and understand the most effective way to incorporate 
them into current treatments. Several type I insulin-like 
growth factor receptor (IGF-IR) targeting agents have 
been in clinical development, including monoclonal anti-
bodies and tyrosine kinase inhibitors, which are reviewed 
by Scagliotti and Novello [11] and Chen and Sharon [12]. 
Figitumumab, a monoclonal antibody against IGF-IR, 
reached a phase III clinical trial in non-adenocarcinoma 
NSCLC that was ended due to poor outcomes [13]. This 
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disappointing outcome leaves researchers asking if a bet-
ter understanding of the role of IGF-IR in lung cancer 
would identify certain biomarkers, histological subtypes, 
and drug combinations or sequences that could improve 
the effectiveness of targeting the IGF-IR as part of lung 
cancer treatment.
There is strong evidence implicating the IGF-IR in 
lung cancer. Molecular studies using lung cancer cell 
lines have shown that disruption of IGF-IR signaling will 
decrease proliferation, cell survival and migration in sev-
eral lung cancer cell lines [14–16]. IGF-IR is also involved 
in tumor initiation since overexpression of the IGF-IR 
in type II alveolar cells or Clara cells was sufficient to 
induce spontaneous tumor formation in mice [17]. Sev-
eral studies have found the IGF-IR to be frequently over-
expressed in NSCLC, ranging from 30 to 84 % of patients 
[18–29]. While many of these studies did not find high 
IGF-IR expression to be associated with overall sur-
vival, it has been associated with progressive disease [18, 
29–31], larger tumor size [23, 26], recurrence [24], and 
brain metastasis [32]. Additionally, high IGF-1 and low 
IGFBP-3 have been associated with poor outcome [33–
39]. This suggests that increased activation of the IGF 
axis contributes to lung cancer progression; therefore, 
targeting the receptor would be an effective therapeutic 
strategy. Furthermore, activation of the IGF-axis via the 
IGF-IR has been identified as a mechanism of resist-
ance to EGFR targeted therapies [40–45] and to cisplatin 
[46–48].
The IGF-IR is a tyrosine kinase receptor which exists 
as a dimer (α2β2): two monomers consisting of an alpha 
subunit and a beta subunit that are joined by disulfide 
bonds [49]. The IGF-IR signals through two main path-
ways, the PI3K/AKT pathway and the MAPK/ERK path-
way [50, 51]. The IGF-IR will form heterodimers with the 
closely related insulin receptor (IR), which shares 60  % 
structural similarity [52–54]. The IGF-IR responds to 
ligand stimulation by IGF-I, IGF-II, and insulin. While 
the IR is primarily activated by insulin, it will also bind to 
IGF-II and can bind both IGF-I and IGF-II when part of 
a heterodimer with IGF-IR [55–60]. Since both IGF-I and 
IGF-II are reported to be important activators of IGF-IR 
signaling in lung cancer [61–64], there is a good ration-
ale for targeting the IR as well as the IGF-IR in order to 
achieve complete inhibition of the IGF axis. Addition-
ally, in breast cancer cells and Ewing sarcoma the IR was 
identified as a mechanism of resistance to IGF-IR specific 
monoclonal antibodies [65, 66]. There may be a thera-
peutic benefit to dual inhibition of both receptors over 
IGF-IR specific monoclonal antibodies. BMS-754807 is 
an ATP competitive inhibitor that targets both the IGF-
IR and the IR [67, 68].
This study evaluated the efficacy of BMS-754807 
alone, and in combination with cisplatin or carboplatin, 
on two NSCLC cell lines in  vitro. Our findings showed 
that BMS-754807 significantly inhibited IGF-IR/IR, AKT 
and ERK1/2 phosphorylation and reduced the survival 
of both NSCLC cell lines evaluated. BMS-754807 signifi-
cantly increase apoptosis in both A549 and NCI-H358 
cells and significantly reduced proliferation in A549 cells. 
In A549 but not NCI-H358 cells, BMS-754807 induced 
synergistic cytotoxicity when combined with cisplatin 
or carboplatin. These findings demonstrate the benefit 
of inhibiting IGF-IR/IR signaling in a pre-clinical setting 
and suggest inhibiting IGF-IR/IR signaling should be fur-




Human lung cancer cell lines, A549 and NCI-H358, 
were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). A549 and NCI-H358 cells were 
cultured in RPMI 1640 medium supplemented with 10 % 
FBS and 1 % antibiotic/antimycotic (v/v) (Life Technolo-
gies, Burlington, ON). Cell were maintained in incuba-
tors at 37  °C and 5  % carbon dioxide. Cell identity was 
confirmed through STR profiling (The Centre for Applied 
Genomics at The Hospital for Sick Children, Toronto, 
ON).
BMS-754807 was purchased from Sellek Chemicals 
(Houston, TX). Cisplatin and carboplatin were both pur-
chased from Sigma-Aldrich (Oakville, ON). BMS-754807 
was dissolved in DMSO (Sigma-Aldrich, Oakville, ON) 
and stored at −20  °C while  cisplatin was dissolved in 
saline and carboplatin was dissolved in water. Cispl-
atin and carboplatin solutions were made fresh for each 
experiment, and stored at 4  °C for the duration of the 
experiment.
Western blotting
Following treatment with BMS-745807, adherent cells 
were lysed, protein was isolated and western blots per-
formed as previously described [69]. Primary antibodies 
were used against IGF-IRβ (1:1000; cat# 3027), phos-
pho-IGF-IR (Tyr1135/1136)/IR (Tyr1150/1151) (1:500; 
cat# 3025), phospho-Akt(Ser473) (1:1000; cat# 4060), 
phospho-ERK1/2 (Thr202/Tyr204) (1:500; cat# 4377), 
and β-actin (1:5000; cat# 4970) (Cell Signaling Tech-
nology, Danvers, MA) overnight at 4  °C. An anti-rabbit 
secondary antibody (1:2000; cat# 7074) (Cell Signaling 
Technology, Danvers, MA) was used for 1  h at room 
temperature. Membranes were visualized using chemi-
luminescence substrate (PerkinElmer, Inc., Waltham, 
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MA) and a FluorChem 8800 gel documentation system 
(Alpha Innotech—ProteinSimple, Toronto, ON) or a 
ChemiDoc XRS  +  imaging system (Bio-Rad Laborato-
ries, Mississauga, ON). For western blots captured using 
the FluorChem 8800 gel documentation, densitometry of 
the bands was determined using AlpahEase FC software 
(Alpha Innotech—ProteinSimple, Toronto, ON) while 
western blots captured using the ChemiDoc XRS +  gel 
documentation, densitometry of the bands was deter-
mined using ImageLab 5.2.1 software (Bio-Rad Laborato-
ries, Mississauga, ON).
WST‑1 Assay
Cells were plated in a 96 well plate at a density of 2500 
cells/well, and allowed to adhere for 4  h. BMS-754807, 
cisplatin, or carboplatin were added either alone or in 
combination or a solvent only control was added (0.1 % 
of total volume). Drugs and media were refreshed every 
24 h. At 72 h, cell viability reagent WST-1 (Roche, Mis-
sissauga, ON) was added and absorbance was read using 
Universal Microplate Reader EL800 (Bio-Tek Instur-
ments, Inc., Winooski, VT) after a 3 h incubation.
Analysis of single and combination drug response
Cell viability determined with WST-1 (Roche, Missis-
sauga, ON) assay after single agent and combination 
treatments with BMS-754807, cisplatin, and carboplatin 
were used to determine the IC50 and Combination Indi-
ces (CI) as calculated using Calcusyn software (Biosoft, 
Cambridge, UK). For combination effects: a synergistic 
effect is considered for a CI < 1; an additive effect is con-
sidered for a CI =  1; and an inhibitory effect is consid-
ered for a CI > 1.
Immunofluorescence
Cells were plated on coverslips in 6-well dishes at a den-
sity of 0.5–1 × 105 cells/well, allowed to adhere overnight, 
then treated with 0.5 μM of BMS-754807), or DMSO only 
(to 0.1  % v/v of total volume). Cells were fixed at 24  h 
post-treatment in 10  % buffered formalin (Fisher Sci-
entific, Ottawa, ON) for 1  h. Cells were washed in PBS, 
permeabilized in 0.5  % Triton-X in PBS, and blocked in 
5  % BSA in PBS. Then the cells were incuabated in pri-
mary antibodies against the proliferation marker Ki67 
(1:400; cat# Ab15580) (Abcam, Toronto, ON) or apoptosis 
marker cleaved caspase 3 (1:200; cat# Ab3623) (Millipore, 
Etobicoke, ON) overnight at 4  °C. Cells were incubated 
with a fluorescent anti-rabbit secondary antibody (1:200; 
cat# A-21207) (Life Technologies, Burlington, ON) for 
1  h at room temperature. Dapi nuclear stain (Life Tech-
nologies, Burlington, ON) was used as a counterstain, and 
coverslips were mounted using Prolong-gold (Life Tech-
nologies, Burlington, ON). Images were captured using 
Olympus BX61 microscope and Metamorph software 
(Molecular Devices, Sunnyvale, CA). Proliferation and 
apoptosis rates within cell populations were quantified by 
manual counts of the number of cells staining positive for 
Ki67 or cleaved caspase 3, respectively, and expressed as 
percentages relative to the total number of cells present as 
revealed by nuclear DAPI staining.
Wound healing assay
Cells were plated on 12 well plates at a density of 
2.0 ×  105 cells/well and cells typically reached 90–95 % 
confluency the following day. A wound was made 
through the centre of the well and cells were treated with 
0.5 μM of BMS-754807, or solvent only (to 0.1 % v/v of 
total volume). Drugs and media were refreshed and 
wound closure was measured every 24  h. Images were 
captured using Olympus IX71 microscope and Q-Cap-
ture software (Q-Imaging, Surrey, BC).
Statistics
All experiments were repeated in triplicate or quadrupli-
cate. Statistical analysis was performed using Graphpad 
Prism 5 (Graphpad Software, Inc., La Jolla, CA). Means 
were compared using a one-way ANOVA and post hoc 
Dunnett’s test when multiple groups were compared back 
to a control value or a paired Student’s T test when two 
means were compared. Error is represented by Standard 
Error of Measurement (SEM). Statistical significance is 
noted as p < 0.05.
Results
IGF‑IR Activity is Inhibited by BMS‑754807
A549 and NCI-H358 cells were treated with the dual 
IGF-IR/IR inhibitor BMS-754807 under regular growth 
conditions. When BMS-754807 was used at concentra-
tions of 0.25 and 0.5 μM, the levels of activated IGF-IR/
IR (pIGF-IR/IR) were reduced within 4  h, and a signifi-
cant reduction in pIGF-IR/IR was observed at 24  h in 
both cell lines suggesting BMS-754807 inhibited IGF-IR/
IR activation (Fig.  1a–h). Furthermore, treatment with 
BMS-754807 caused a concurrent decrease in phospho-
rylated AKT in both lung cancer cell lines (Fig.  1a–h). 
ERK phosphorylation was significantly reduced following 
administration of 0.5 μM but not 0.25 μM BMS-754807 
(Fig. 1a–h).
To compare protein levels in A549 and NCI-H358 cells 
protein bands from the 4  h No Treatment groups were 
quantified. The IGF-IR protein was detected in both cell 
lines with A549 cells expressing more IGF-IR protein 
than NCI-H358 cells (Fig.  1a, b, i). A549 cells also pos-
sessed higher levels of phosphorylated IGF-IR/IR (pIGF-
IR/IR) and phosphorylated AKT (pAKT) than NCI-H358 
cells (Fig. 1a, b, i).
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Treatment with BMS‑754807 inhibits proliferation 
and induces apoptosis
Concentration–response curves were generated to deter-
mine the sensitivity of each lung cancer cell line to BMS-
754807. BMS-754807 administration was sufficient to 
reduce cell viability in both A549 and NCI-H358 cells 
(Fig.  2a). The IC50 values were determined using Cal-
cusyn software (Table  1) to be 0.76  μM for NCI-H358 
cells and 1.08 μM for A549 cells. In order to determine 
the specific cause of this reduction of cell viability, prolif-
eration and apoptosis rates were determined in A549 and 
NCI-H358 cells following treatment with 0.5  μM BMS-
754807 by immunoflourescence for Ki67 (Fig.  2b) or 
cleaved caspase 3 (Fig. 2c), respectively. BMS-754807 sig-
nificantly inhibitied proliferation in A549 cells (Fig.  2d) 
but not NCI-H358 cells (Fig. 2e). Treatment with 0.5 μM 
BMS-754807 significantly increased apoptosis in both 
A549 (Fig. 2f ) and NCI-H358 cells (Fig. 2g).
BMS‑754807 impairs wound closure
To determine whether inhibition of IGF-IR/IR signal-
ing influences wound closure, wound assays were per-
formed following BMS-754807 treatment. Representative 
images of A549 cells shown at time 0  h (Fig.  3a, c) and 
48 h (Fig. 3b, d) after treatment with the DMSO control 
(Fig.  3a, b) or 0.5  μM BMS-754807 (Fig.  3c, d). There 
was a minor, but statistically significant, impairment of 
wound closure in NCI-H358 and A549 cells treated with 
0.5 μM BMS-754807 (Fig. 3e, f ).
Treatment with BMS‑754807 or platinum 
chemotherapeutics reduces cell survival
Concentration–response curves were generated to deter-
mine the sensitivity of each lung cancer cell line to cis-
platin and carboplatin when they were used as single 
agents. Both cell lines were sensitve to growth inhibi-
tion by cisplatin (Fig.  4a) and carboplatin (Fig.  4b) in a 
concentration dependant manner. The IC50 values were 
determined using Calcusyn software (Table 1). A549 cells 
were more sensitive to platinum chemotherapeutics than 
NCI-H358 cells, with IC50 values of 3.3 and 14.9 μM for 
cisplatin and 65.3 and 202.7 μM for carboplatin, respec-
tively. Both cell lines were more sensitive to cisplatin than 
to carboplatin as reflected by the lower IC50 values for 
cisplatin compared to carboplatin.
BMS‑754807 synergizes with platinum chemotherapeutics 
to reduce A549 Cell viability
To determine if the addition of BMS-754807 could 
enhance the anticancer effects of platinum based chem-
otherapeutics at low concentrations, BMS-754807 was 
combined simultaneously with either cisplatin or car-
boplatin and the effects on cell viability were compared 
to those of each single agent. Three concentrations of 
BMS-754807 (0.01, 0.1, 0.25  μM in A549 cells and 2.5, 
5.0, 10 µM in NCI H358 cells) were combined with three 
concentrations of cisplatin (0.5, 1, 2.5 μM) or carboplatin 
(10, 25, 50  μM in A549 cells and 50, 75 and 100  µM in 
NCI H358 cells), which based on the single agent concen-
trations were responsible for no more than approximately 
25–30  % decrease in cell viability. At all concentrations 
of cisplatin and carboplatin used, the addition of BMS-
754807 enhanced the effects of cisplatin and carboplatin 
(Fig.  5a, b). Combination indices were calculated using 
Calcusyn software to determine the nature of the inter-
action between cisplatin and BMS-754807 or carboplatin 
and BMS-754807. Representative plots of these inter-
actions are presented in Fig.  5c, d. Combination indi-
ces <1 suggest synergistic interaction between the two 
drugs while combination indices of approximately 1 sug-
gest additive drug interactions and combination indices 
>1 suggest antagonistic drug interactions. Based on the 
data presented in Fig. 5c, d, the combination of 0.25 μM 
BMS-754807 with cisplatin or carboplatin resulted in a 
synergistic reduction of cell survival in A549 cells (black 
symbols) but only additive or antagonistic interactions in 
NCI-H358 cells (white symbols). A complete list of the 
drug interactions for all the drug combinations tested are 
presented in Tables 2 and 3.
Discussion
The IGF-IR is frequently expressed at high levels in 
NSCLC and thus represents a potential therapeutic tar-
get. One compound that targets IGF-IR (as well as IR) is 
BMS-754807 and this drug was evaluated in two human 
non-small cell lung cancer cell lines, A549 and NCI-
H358. Both A549 and NCI-H358 cells express IGF-IR 
protein and the IGF-IR is phosphorylated in both cell 
lines under normal growth conditions with A549 cells 
containing higher levels of IGF-IR and phosphorylated 
IGF-IR than the NCI-H358 cells. BMS-754807 signfi-
cantly reduced, IGF-IR/IR, AKT and ERK phosphoryla-
tion in both cell lines with the most dramatic effect being 
the reduction in AKT phosphorylation. When Wittman 
et al. [67] first reported the development of BMS-754807 
they reported it to be more effective at ERK inhibition 
than AKT with IC50 of 13 and 22 nM, respectively. How-
ever, subsequent reports in cell lines suggest the BMS-
754807 is a more potent inhibitor of AKT than ERK 
phosporylation [68] which is consistent with our results. 
Furthermore, BMS-754807 was also reported to prefer-
entialy inhibit the AKT pathway in breast cancer [70] and 
prostate cancer cells [71].
As a single agent, BMS-754807 effectively suppressed 
the survival of both A549 and NCI-H358 cells. This 
decrease in survival likely results from a significant 
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Fig. 1 IGF-IR is expressed in lung cancer cells and its activity is inhibited by treatment with BMS-754807. Western blots of pIGF-IR/IR, IGF-IR, pAKT, AKT, 
pERK and ERK in A549 (a, c) and NCI-H358 (b, d) cells 4 (a, b) or 24 (c, d) hours after administration of 0.25 or 0.5 μM of BMS-754807. The bar graphs 
(e–h) represent the quantification of three independent western blots with the bars representing the means and the error bars representing SEM. The 
protein levels were normalized to the DMSO control group for each protein; the no treatment group was not quantified. β-actin was used as a load-
ing control in the western blots and *p < 0.05 as determined by a Dunnett’s test. The bands from the 4 h No Treatment groups were quantified and 
are presented as the mean ± SEM for each protein relative to β-actin to illustrate the differences in protein levels in A549 and NCI-H358 cells (i)





Fig. 2 Treatment with BMS-754807 reduces cell viability in a concentration dependent manner. A549 (black line) and NCI-H358 (grey line) cells were 
treated with various concentrations of BMS-754807 every 24 h for 72 h. Cell viability was then measured with a WST-1 assay (a; n = 3). Immunofluo-
rescence for Ki67 and cleaved caspase 3 were used to evaluate the impact of BMS-754807 on these cellular properties. A representative image of 
Ki67 (b; green color) and cleaved caspase 3 (c; red color) are presented as overlay images of cell nuclei stained with 4′,6-diamidino-2-phenylindole 
(DAPI, blue color). Arrows highlight some of the positive cells in each image. The number of Ki67 positive cells (d, e) and cleaved caspase 3 positive 
cells (f, g) along with the total number of cells were counted 24 h after treatment with 0.5 μM BMS-754807 and are presented as relative prolifera-
tion (d, e) or relative apoptosis (f, g) in A549 (d, f) and NCI-H358 (e, g) cells. The data is presented as mean ± SEM (n = 4) and the percentage of 
positive cells have been normalized to the DMSO control. *p < 0.05 as determined by a paired Student’s T-test
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increase in apoptosis induced by BMS-754807 in both 
A549 and NCI-H358 cells. BMS-754807 also significantly 
reduced proliferation in A549 but not NCI-H358 cells. 
This is the first report of the effects of BMS-754807 on 
survival, proliferation and apoptosis in A549 and NCI-
H358 cells. BMS-754807 action has been evaluated in 
several other human NSCLC lines with similar IC50 
Table 1 IC50 concentrations for  BMS-754805, cisplatin, 
and carboplatin
Cell line Drug (µM)
BMS‑754808 Cisplatin Carboplatin
A549 1.08 3.33 65.29




Fig. 3 BMS-754807 reduces wound closure of lung cancer cells. Scratch wounds were made on near confluent plates of lung cancer cells. Cells 
were treated with BMS-754807 every 24 h, and wound closure was measured over 48–72 h. Representative images from A549 cells at 0 h (a, c) or 
48 h (b, d) after treatment with either an appropriate concentration of DMSO or 0.5 μM of BMS-754807. Quantification of the relative scratch wound 
closure at 48 h in A549 (e) or at 72 h in NCI-H358 (f) cells was determined by measuring the remaining area not filled with cells and presenting this 
relative to the area of the scratch at time 0 h. Data represents mean ± SEM (n = 4), *p < 0.05 as determined by a paired Student’s T-test
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Fig. 4 Treatment with platinum chemotherapeutics reduced cell viability in a concentration dependent manner. A549 (black line) and NCI-H358 
(grey line) cells were treated with various concentrations of cisplatin (a), or carboplatin (b). Media and drugs were refreshed every 24 h for 72 h, then 
cell viability was measured with a WST-1 assay. All values are relative to the DMSO control and are presented as mean ± SEM (n = 3)
a b
c d
Fig. 5 BMS-754807 synergizes with platinum based chemotherapeutics to enhance killing of A549 cells. Lung cancer cells were treated with a com-
bination of BMS-754807 and either cisplatin (a, c) or carboplatin (b, d). Media and drugs were refreshed every 24 h for 72 h, then cell viability was 
measured using a WST-1 assay. Data illustrated in (a, b) are representative graphs of A549 cells treated BMS-754807 in combination with cisplatin 
(a) or carboplatin (b). This data is presented as mean ± SEM (n = 4). Combination indices were calculated using Calcusyn software and the data for 
cisplatin in combination with 0.25 μM of BMS-754807 is presented in (e) while the data for carboplatin in combination with 0.25 μM of BMS-754807 
is presented in (f). A549 cells are plotted as black symbols while NCI-H358 cells are plotted as white symbols. The complete list of the interactions of 
all BMS-754807 concentrations with either cisplatin or carboplatin are presented in Tables 2 and 3
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values (0.5–5 µM range) however proliferation and apop-
tosis were not specifically assessed [68]. Another novel 
finding of this study was that BMS-754807, as a single 
agent, could suppress wound closure. Since several stud-
ies have demonstrated an important role for IGF-IR in 
the motility and invasion of lung cancer cells [72–76] it 
is possible that BMS-874807 can negatively impact lung 
cancer cell migration and potentially metastais. How-
ever, this finding of reduced wound closure requires con-
firmation as alterations in proliferation and apoptosis 
can influence the rate of wound closure independent of 
migration.
Platinum-based chemotherapeutic agents are com-
monly employed in the treatment of unresectable 
NSCLC [77]. Therefore, we evaluated the efficacy of cis-
platin and carboplatin in A549 and NCI-H358 cells and 
found that both cell lines were more sensitive to cispl-
atin than carboplatin. This is consistent with the study by 
Mahalingham et al. [8] that reported cisplatin was more 
effective than carboplatin in the treatment of NSCLC. To 
evaluate whether BMS-754807 could enhance the effects 
of platinum chemotherpeutics, A549 and NCI-H358 cell 
survival was assessed following simultaneous administra-
tion of either BMS-754807 and cisplatin or BMS-754807 
and carboplatin. In almost all the combinations tested, 
administration of BMS-754807 with cisplatin or carbo-
platin resulted in a syngersitic reduction in cell survival 
in A549 cells. In NCI-H358 cells, combinations of BMS-
754807 with cisplatin or carboplatin resulted in additive 
or antagonistic drug interactions with respect to cell sur-
vival. It remains unclear why the combinations of BMS-
754807 with the platinum agents was more effective in 
the A549 cells. A549 cells express higher levels of IGF-
IR than NCI-H358 cells and thus it is possible that A549 
cells are more reliant on IGF-IR signaling for proliferation 
and survival. It is also possible that the intrinsic insensi-
tivity of NCI-H358 cells to platinum chemotherapeutics 
(IC50 for both cisplatin and carboplatin were consider-
ably higher for NCI-H358 cells compared to A549 cells) 
impacted the interactions at the concentrations evalu-
ated. A final potential explanation is that the different 
mutational profile of the two cells could influence drug 
interaction. While both cell lines harbour a mutation in 
K-ras, A549 cells have a mutation in Cdkn2a but contain 
wild type p53 while NCI-H358 express mutant p53 but 
wild type Cdkn2a (atcc.org). The only other study evalu-
ating BMS-754807 in combination with chemotherapy 
in NSCLC found that BMS-754807 in combination with 
gefitinib resulted in synergistic reduction in cell survival 
in the human NSCLC cell line, NCI-H292 [78]. In small 
Table 2 Drug interaction between  cisplatin and  BMS-
754807
a Combination index <1 = synergistic interaction, combinations index ~1
 = additive interaction, combination index >1 = antagonistic interaction
Cell line Cisplatin (μM) BMS‑754807 (µM) Interactiona
A549 0.5 0.01 Synergistic
A549 1.0 0.01 Synergistic
A549 2.5 0.01 Synergistic
A549 0.5 0.1 Synergistic
A549 1.0 0.1 Synergistic
A549 2.5 0.1 Synergistic
A549 0.5 0.25 Synergistic
A549 1.0 0.25 Synergistic
A549 2.5 0.25 Synergistic
NCI-H358 2.5 0.001 Antagonistic
NCI-H358 5.0 0.001 Antagonistic
NCI-H358 7.5 0.001 Antagonistic
NCI-H358 2.5 0.1 Additive
NCI-H358 5.0 0.1 Additive
NCI-H358 7.5 0.1 Additive
NCI-H358 2.5 0.25 Antagonistic
NCI-H358 5.0 0.25 Additive
NCI-H358 7.5 0.25 Additive
Table 3 Drug interaction between  carboplatin and  BMS-
754807
a combination index <1 = synergistic interaction, combinations index ~1
 = additive interaction, combination index >1 = antagonistic interaction
Cell line Carboplatin (µM) BMS‑754807 (µM) Interactiona
A549 10 0.01 Synergistic
A549 25 0.01 Antagonistic
A549 50 0.01 Synergistic
A549 10 0.1 Synergistic
A549 25 0.1 Additive
A549 50 0.1 Synergistic
A549 10 0.25 Synergistic
A549 25 0.25 Synergistic
A549 50 0.25 Synergistic
NCI-H358 50 0.001 Antagonistic
NCI-H358 75 0.001 Antagonistic
NCI-H358 100 0.001 Additive
NCI-H358 50 0.1 Antagonistic
NCI-H358 75 0.1 Antagonistic
NCI-H358 100 0.1 Additive
NCI-H358 50 0.25 Antagonistic
NCI-H358 75 0.25 Antagonistic
NCI-H358 100 0.25 Additive
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cell lung cancer (SCLC) targeting the IGF-IR using the 
monoclonal antibody NVP-ADW742 sensitizes SCLC 
cell lines to the effects of etoposide and carboplatin [79].
Conclusions
In summary, this research demonstrates for the first time, 
the efficacy of BMS-754807 as a single agent in A549 
and NCI-H358 cells and in combination with platinum-
based chemotherapeutic agents in A549 cells. Therefore, 
BMS-754807 may be an effective therapeutic agent for 
the treatment of lung cancer, particularly in patients with 
lung tumors expressing high levels of IGF-IR.
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